Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424688 | 0.88 | TGFBR1 (0.40) | TRPV1MAPK3TGFBR1F2F10 | |
| SCHEMBL15976495 | 0.87 | ACP1 (0.40) | SUCNR1TRPV1MAPK3TGFBR1ACP1 | |
| SCHEMBL12424821 | 0.87 | TGFBR1 (0.42) | TRPV1TGFBR1ACP1 | |
| SCHEMBL12425320 | 0.86 | CYP1A2 (0.41) | TRPV1MAPK3TGFBR1F2F10 | |
| SCHEMBL12425347 | 0.85 | TRPV1 (0.42) | TRPV1MAPK3CLK4 | |
| SCHEMBL12424685 | 0.77 | TGFBR1 (0.39) | TRPV1MAPK3CDK5CLK4TGFBR1 | |
| SCHEMBL14227397 | 0.75 | MAP4K1 (0.32) | TRPV1MAPK3CLK4ACP1SYK | |
| SCHEMBL12426290 | 0.74 | TGFBR1 (0.39) | TRPV1MAPK3CLK4TGFBR1 | |
| SCHEMBL12424786 | 0.74 | EGFR (0.44) | SUCNR1TGFBR1 | |
| SCHEMBL12425348 | 0.74 | EGFR (0.40) | SUCNR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | SUCNR1 2302/4885TRPV1 4168/4885MAPK3 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.